198 related articles for article (PubMed ID: 31044096)
1. Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis.
Skandamis A; Kani C; Markantonis SL; Souliotis K
J Drug Assess; 2019; 8(1):55-61. PubMed ID: 31044096
[No Abstract] [Full Text] [Related]
2. Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments.
Fleetwood K; McCool R; Glanville J; Edwards SC; Gsteiger S; Daigl M; Fisher M
J Manag Care Spec Pharm; 2017 Mar; 23(3-b Suppl):S5-S16. PubMed ID: 28287346
[TBL] [Abstract][Full Text] [Related]
3. Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis.
Di Martino E; Provenzani A; Vitulo P; Polidori P
Ann Pharmacother; 2021 Jun; 55(6):723-731. PubMed ID: 33054319
[TBL] [Abstract][Full Text] [Related]
4. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis.
Rochwerg B; Neupane B; Zhang Y; Garcia CC; Raghu G; Richeldi L; Brozek J; Beyene J; Schünemann H
BMC Med; 2016 Feb; 14():18. PubMed ID: 26843176
[TBL] [Abstract][Full Text] [Related]
5. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
[TBL] [Abstract][Full Text] [Related]
6. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials.
Wu X; Li W; Luo Z; Chen Y
BMC Pulm Med; 2024 Jan; 24(1):58. PubMed ID: 38281037
[TBL] [Abstract][Full Text] [Related]
8. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
Ikeda S; Sekine A; Baba T; Katano T; Tabata E; Shintani R; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
BMC Pulm Med; 2019 Apr; 19(1):78. PubMed ID: 30975118
[TBL] [Abstract][Full Text] [Related]
9. Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.
Canestaro WJ; Forrester SH; Raghu G; Ho L; Devine BE
Chest; 2016 Mar; 149(3):756-66. PubMed ID: 26836914
[TBL] [Abstract][Full Text] [Related]
10. Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis.
Pitre T; Mah J; Helmeczi W; Khalid MF; Cui S; Zhang M; Husnudinov R; Su J; Banfield L; Guy B; Coyne J; Scallan C; Kolb MR; Jones A; Zeraatkar D
Thorax; 2022 Dec; 77(12):1243-1250. PubMed ID: 35145039
[TBL] [Abstract][Full Text] [Related]
11. Choice of Methodology Impacts Outcome in Indirect Comparisons of Drugs for Idiopathic Pulmonary Fibrosis.
Scott DA; Loveman E; Colquitt JL; O'Reilly K
Medicina (Kaunas); 2019 Aug; 55(8):. PubMed ID: 31390809
[No Abstract] [Full Text] [Related]
12. Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis.
Ren H; Wang K; Yang H; Gao L
Saudi Med J; 2017 Sep; 38(9):889-894. PubMed ID: 28889145
[TBL] [Abstract][Full Text] [Related]
13. Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment.
Cerri S; Monari M; Guerrieri A; Donatelli P; Bassi I; Garuti M; Luppi F; Betti S; Bandelli G; Carpano M; Bacchi Reggiani ML; Tonelli R; Clini E; Nava S
Respir Med; 2019 Nov; 159():105803. PubMed ID: 31670147
[TBL] [Abstract][Full Text] [Related]
14. South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
Barratt SL; Mulholland S; Al Jbour K; Steer H; Gutsche M; Foley N; Srivastava R; Sharp C; Adamali HI
Front Pharmacol; 2018; 9():1480. PubMed ID: 30618768
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis.
Huh JY; Lee JH; Song JW
Front Pharmacol; 2023; 14():1301923. PubMed ID: 38192410
[No Abstract] [Full Text] [Related]
16. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
Vancheri C; Kreuter M; Richeldi L; Ryerson CJ; Valeyre D; Grutters JC; Wiebe S; Stansen W; Quaresma M; Stowasser S; Wuyts WA;
Am J Respir Crit Care Med; 2018 Feb; 197(3):356-363. PubMed ID: 28889759
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study.
Vianello A; Salton F; Molena B; Turato C; Graziani ML; Braccioni F; Frassani V; Sella D; Pretto P; Paladini L; Sukthi A; Confalonieri M
J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32033147
[TBL] [Abstract][Full Text] [Related]
18. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
[TBL] [Abstract][Full Text] [Related]
19. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study.
Cameli P; Refini RM; Bergantini L; d'Alessandro M; Alonzi V; Magnoni C; Rottoli P; Sestini P; Bargagli E
Front Mol Biosci; 2020; 7():581828. PubMed ID: 33102528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]